Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovulation induction with human menopausal gonadotropins--a changing scene.

J Ginsburg1, P Hardiman

  • 1Department of Endocrinology, Royal Free Hospital and Medical School, London, UK.

Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|March 1, 1991
PubMed
Summary

Human menopausal gonadotropin (hMG) treatment effectively helps women with clomiphene-resistant infertility achieve conception and live birth. Despite risks like multiple pregnancies, hMG remains a safe and viable option for eligible patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal mind-mindedness and infant oxytocin are interrelated and negatively associated with postnatal depression.

Development and psychopathology·2024
Same author

Pre-pregnancy weight loss in women with obesity requesting removal of their intra-uterine contraceptive device in order to conceive: a pilot study of full meal replacement.

Clinical obesity·2018
Same author

The effect of thawing protocols on follicle conservation in human ovarian tissue cryopreservation.

Cryo letters·2017
Same author

Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort.

British journal of cancer·2009
Same author

The association between polycystic ovaries and endometrial cancer.

Human reproduction (Oxford, England)·2005
Same author

Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2005

Area of Science:

  • Reproductive Endocrinology
  • Infertility Treatment

Background:

  • Human menopausal gonadotropin (hMG) treatment aims to stimulate follicular development and ovulation but often leads to multiple follicular development.
  • Complications such as multiple pregnancies and hyperstimulation syndrome arise from bypassing hypothalamic-pituitary feedback and the long half-life of human chorionic gonadotropin (hCG).

Purpose of the Study:

  • To evaluate the efficacy and safety of hMG therapy in women with clomiphene-resistant infertility.
  • To analyze factors influencing conception, live birth, miscarriage, and multiple pregnancy rates.

Main Methods:

  • Retrospective review of hMG therapy outcomes in 260 consecutive women with clomiphene-resistant infertility from 1977 to 1989.
  • Analysis of conception, live birth, miscarriage, and multiple pregnancy rates after six treatment cycles.

Related Experiment Videos

  • Assessment of influencing factors including infertility cause, age, weight, and sperm parameters.

    • Main Results:

    • Conception and live birth rates were 45.7% and 43.3%, respectively, after six hMG cycles.
    • Miscarriage rate was 18.6%, and multiple pregnancy rate was 19.3%.
    • Conception rates declined over the study period, except in women with regular anovulatory cycles, coinciding with increased patient age, weight, and male subfertility.

    Conclusions:

    • Human menopausal gonadotropin (hMG) is an effective and safe treatment for women with clomiphene-resistant infertility and patent fallopian tubes.
    • Treatment outcomes are influenced by infertility etiology, patient age, body weight, and seminal parameters.
    • A declining conception trend observed over time may be linked to demographic shifts in the patient population.